Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies' stock has been impacted by inducement grants announced in April, March, and February 2026, and the release of full-year 2025 financial results and a corporate update in March 2026. The stock has shown significant growth over the past year, gaining 285.8%. However, there has been insider selling activity by executives.

As a clinical-stage biotechnology company focused on research, development, and clinical evaluation of gene therapies, Taysha Gene Therapies, Inc. does not have commercialized products, and therefore, there is no information available regarding demand seasonality for its products or services.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing and commercializing AAV-based gene therapies for severe monogenic CNS diseases, with a primary focus on Rett syndrome. Their lead clinical program is TSHA-102, a gene transfer therapy for Rett syndrome. The company also has a pipeline of other gene therapy candidates for diseases such as giant axonal neuropathy, CLN7 disease, CLN1 disease, SLC13A5 deficiency, tauopathies, Angelman syndrome, and Fragile X syndrome.

Taysha Gene Therapies, Inc. is headquartered in Dallas, Texas, and has a laboratory facility in Morrisville, North Carolina, indicating its primary operational and research presence is within the United States.

Taysha Gene Therapies has a positive reputation, particularly concerning TSHA-102 for Rett syndrome, which has received multiple regulatory designations, including Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission, and ILAP designation from the Medicines and Healthcare products Regulatory Agency in the United Kingdom. The company emphasizes its commitment to addressing severe unmet medical needs. No specific events negatively impacting Taysha Gene Therapies' brand reputation in the past year were found in the provided information.

Taysha Gene Therapies, Inc. has significant institutional ownership, with 198 institutional owners holding a total of 271,047,922 shares. Major institutional shareholders include Ra Capital Management, L.p., Avoro Capital Advisors LLC, BlackRock, Inc., Morgan Stanley, RTW Investments, Lp, Vestal Point Capital, LP, Goldman Sachs Group Inc, Fmr Llc, Vanguard Group Inc, and State Street Corp. Individual insider ownership accounts for 8.89% of the company's shares, with top insider holders including R.A. Ii Session, Sean P. Nolan, and Paul B Manning.